Please select the option that best describes you:
Topics:
Gastrointestinal Cancers • Gastric Cancer • Esophageal Cancer • Medical Oncology • Immunotherapy • Biologic Therapy/Immunobiology
What are your considerations for choice of immunotherapy agent with patients with metastatic pMMR HER2- esophageal/GEJ/gastric adenocarcinoma with CPS >=10?
Are there meaningful differences in the CHECKMATE 649 and KEYNOTE 590 studies to guide this decision?
Answer from: Medical Oncologist at Academic Institution
I alluded to this earlier. Although both CheckMate 649 and KEYNOTE 590 included esophageal cancer, there were caveats. Specifically, in CheckMate 649, there were relatively few patients with esophageal adenocarcinoma. The positive results of CM-649 were clearly driven by gastric adenocarcinoma, part...
Sign in or Register to read more
Answer from: Medical Oncologist at Community Practice
There are no meaningful differences in CheckMate 649 (nivolumab + chemotherapy) and KEYNOTE 590 for patients whose CPS >=10. Either regimens are reasonable choices as both improve OS, PFS, and ORR compared to chemotherapy.